

1     **SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the**  
2             **subsequent incidence of COVID-19 in 100,000 healthcare**  
3             **workers: do antibody positive healthcare workers have less**  
4             **reinfection than antibody negative healthcare workers?**

5

6     Short Title: The impact of detectable anti-SARS-CoV-2 antibody on the incidence of COVID-  
7     19

8

9     **Authors and affiliations**

10    S. Wallace\*<sup>§</sup>, V. Hall\*, A. Charlett, P.D. Kirwan, M.J. Cole, M. Shrotri, S. Rokadiya, B. Oguti,  
11    A. Vusirikala, M. Zambon, T. Brooks, M. Ramsay, C.S. Brown, M.A. Chand, S. Hopkins

12    \* Joint first author

13    <sup>§</sup>Corresponding Author

14    Affiliation: COVID-19 response, Public Health England, London, UK

15

16    **Abstract**

17    **Background**

18    The overall risk of reinfection in individuals who have previously had COVID-19 is unknown.

19    To determine if prior SARS-CoV-2 infection (as determined by at least one positive  
20    commercial antibody test performed in a laboratory) in healthcare workers confers future  
21    immunity to reinfection, we are undertaking a large-scale prospective longitudinal cohort  
22    study of healthcare staff across the United Kingdom.

23

24 **Methods**

25 Population and Setting: staff members of healthcare organisations working in hospitals in the  
26 UK

27 At recruitment, participants will have their serum tested for anti-SARS-CoV-2 at baseline and  
28 using these results will be initially allocated to either antibody positive or antibody negative  
29 cohorts. Participants will undergo antibody and viral RNA testing at 1-4 weekly intervals  
30 throughout the study period, and based on these results may move between cohorts. Any  
31 results from testing undertaken for other reasons (e.g. symptoms, contact tracing etc.) or  
32 prior to study entry will also be included. Individuals will complete enrolment and fortnightly  
33 questionnaires on exposures and symptoms. Follow-up will be for at least 12 months from  
34 study entry.

35 Outcome: The primary outcome of interest is a reinfection with SARS -CoV-2 during the  
36 study period. Secondary outcomes will include incidence and prevalence (both RNA and  
37 antibody) of SARS-CoV-2, viral genomics, viral culture, symptom history and  
38 antibody/neutralising antibody titres.

39 **Conclusion**

40 This large study will help us to understand the impact of the presence of antibodies on the  
41 risk of reinfection with SARS-CoV-2; the results will have substantial implications in terms of  
42 national and international policy, as well as for risk management of contacts of COVID-19  
43 cases.

44 **Trial Registration**

45 IRAS ID 284460, HRA and Health and Care Research Wales approval granted 22 May  
46 2020.

47 **Key Words**

48 COVID-19, SARS-CoV-2, Antibodies, Reinfection, Healthcare, Staff, Cohort, Protocol

49

## 50 1. Introduction

51 SARS-CoV-2, a novel coronavirus which causes respiratory illness, was first identified in  
52 China in December 2019.(1) Following global spread of the virus, the World Health  
53 Organization declared a national pandemic in March 2020. Globally nearly 64 million cases  
54 have been reported to the World Health Organization by 4 December 2020, with 1,488,120  
55 deaths attributed to COVID-19 (2), and both the virus and the measures put in place to  
56 reduce spread have led to significant economic and societal impacts. Whether individuals  
57 can be re-infected with SARS-CoV-2 is a crucial question both for contact management of  
58 individuals exposed to the virus, but also from the perspective of the implications for the  
59 effectiveness of any vaccine produced.

60 The risk of reinfection for individuals who have previously had COVID-19 is unknown. There  
61 have been a number of case reports which have identified individuals who have been  
62 reinfected with a new and genetically distinct SARS-CoV-2 genome from their original  
63 infection.(3-8) One recent study of the antibody prevalence from three large cross-sectional  
64 surveys in England, measured using a self-administered test, found that over a three month  
65 period population prevalence dropped from 6.0% (5.8, 6.1) to 4.4% (4.3, 4.5), suggesting  
66 waning antibodies in the population.(9) Several longitudinal studies have looked at titres over  
67 time, with one UK based study showing waning of neutralising antibodies over 3 months but  
68 with large differences between individuals (those with more severe disease had higher  
69 antibody titres at their peak)(10), while another study in Iceland demonstrated maintenance  
70 of IgG titres over 4 months.(11) However the implications of these findings are unclear. We  
71 know that other human coronaviruses demonstrate similar patterns of waning titres over  
72 time, with individuals able to be reinfected and shed virus.(12)

73 Many hospitals are choosing to screen certain staff groups regularly for SARS-CoV-2 to  
74 reduce the risk of transmission to patients and colleagues. Healthcare workers have  
75 consistently been found to have higher positive antibody prevalence compared with the

76 general population; published surveys in UK hospital staff have reported prevalences of  
77 24.5% in a Birmingham Hospital(13), and 31%(14) and 44%(15) in London. For a study  
78 examining the risk of reinfection an ideal population to examine this question is one with a  
79 high baseline antibody prevalence, where there is an indication for routine SARS-CoV-2  
80 screening, easy access to testing and likely to be higher ongoing exposure to SARS-CoV-2  
81 in hospitals.

82 The SIREN (**S**arscov2 Immunity & **RE**infection Evaluation**N**) study aims to answer the key  
83 question of whether prior SARS-CoV-2 infection confers future immunity to SARS-CoV-2  
84 reinfection. The study design will also enable important secondary outcomes to be  
85 examined, including antibody titre change over time, incidence of new infections, clinical and  
86 demographic factors correlating with antibody presence, phylogenetic relatedness of  
87 healthcare worker infections and ability to culture viable virus from those who are reinfected.

88

## 89 2. Methods

### 90 2.1. Study design

91 This is a prospective longitudinal cohort study which will enrol up to 100,000 individuals and  
92 follow them up for 12 months with regular data collection. Individuals will be enrolled  
93 between June 2020 and March 2021.

### 94 2.2. Study objectives

95 The overall aim of this study is to determine if prior SARS -CoV-2 infection in health care  
96 workers confers future immunity to reinfection.

97

98 **Primary Objective:** To determine whether the presence of antibody to SARS-CoV-2 (anti-  
99 SARS-CoV-2) is associated with a reduction in the subsequent risk of reinfection over short  
100 term periods (reviewed monthly) and the next year.

#### 101 **Secondary Objectives:**

- 102 1. To estimate the prevalence of SARS-CoV-2 infection in staff working in healthcare  
103 organisations by region, using baseline serological testing at study entry and  
104 symptom history from January 1st 2020 to date of study entry
- 105 2. To estimate the subsequent incidence of symptomatic and asymptomatic SARS-  
106 CoV-2 infection and determine how this varies over time, using regular PCR testing  
107 (combined with any intercurrent symptomatic testing)
- 108 3. To estimate cumulative incidence of new infections in staff working in healthcare  
109 organisations stratified by age, sex, staff group, ethnicity and co-morbidities
- 110 4. To measure the ability to culture viable virus from cases of reinfection diagnosed by  
111 PCR and whether those who are persistently positive on PCR are continuing to shed  
112 viable virus

- 113        5. To use genomic comparison to determine whether healthcare workers who become  
114            PCR-positive for a second time within a defined time frame are experiencing  
115            persistent infection or reinfection
- 116        6. To determine how serological response changes over time
- 117        7. To determine whether there is a relationship between serological response (using  
118            enzyme immunoassay detection of IgG) and the presence of neutralising (protective)  
119            antibodies
- 120        8. To identify serological, demographic or clinical factors that correlate with the  
121            presence of neutralising antibodies, including subsequent disease severity
- 122        9. To investigate the phylogenetic relatedness of SARS-CoV-2 viruses causing staff  
123            working in healthcare organisations infections

124

## 125        2.3.        Participants and recruitment

### 126        **Population**

127        The eligible population are staff members of healthcare organisations. Staff are recruited  
128        from healthcare organisations participating as SIREN sites, and all NHS Trusts/Health  
129        Boards (organisations that manage hospitals) in England, Scotland, Wales and Northern  
130        Ireland have been invited to join. At a later stage, recruitment may be extended to staff from  
131        other healthcare organisations such as primary care organisations and the independent  
132        sector.

### 133        **Eligibility**

134        A participants is eligible to join the study if they are a healthcare organisation staff member  
135        who works in a clinical setting where patients are present, can provide written consent, and

136 is willing to remain engaged with follow-up for 12-months. Temporary short-term staff  
137 members are not eligible.

### 138 **Recruitment and consent**

139 Sites are responsible for recruiting eligible participants, according to their own processes.

140 Sites are recommended to circulate all staff communications inviting volunteers and to

141 monitor the demographics of their cohort as they recruit, aiming to represent their staff

142 population. There are no requirements for quotas or structured sampling.

143 Interested and eligible potential participants are provided with a unique study number and

144 passcode by their site research team and directed to enrol in the study by completing the

145 online consent form and enrolment questionnaire. On completion of the online consent form

146 and enrolment questionnaire, participants join the SIREN cohort. Site research teams are

147 automatically informed of participant enrolment in real-time, and can then contact

148 participants to arrange testing.

149

## 150 **2.4. Data collection**

### 151 **At enrolment**

152 At enrolment participants complete an online questionnaire and submit serum and a nose

153 swab (or nose and throat swab) for SARS-CoV-2 antibody and nucleic acid amplification

154 (NAAT) testing. Participants will have up to 10mls of blood taken by venepuncture at

155 enrolment and follow-up. The questionnaire collects information on participant

156 demographics, work environment, symptom and testing history, participation in clinical trials

157 and known COVID exposures since 1 January 2020.

158 **At follow-up**

159 Participants undergo regular repeat NAAT and antibody testing throughout the study period,  
160 initially at fortnightly intervals, although frequency may be revised (weekly to monthly)  
161 subject to local/national epidemiology and feedback. Participants are sent a link to an online  
162 follow-up questionnaire on a fortnightly basis, with a reminder message sent after 2 days if  
163 the follow-up questionnaire is not completed. These questionnaires capture information on  
164 symptoms, exposures and subsequent enrolment in vaccine or prophylaxis trials.

165 **Testing at SIREN site laboratories and data sources**

166 For all participants NAAT (typically PCR) and antibody testing is undertaken locally at the  
167 laboratory used by their healthcare organisation. The healthcare organisation is responsible  
168 for issuing results to the participants as per local procedures. Testing platforms, including  
169 choice of antibody assay, is determined locally.

170 All laboratories for SIREN participating sites submit their antibody and antigen testing data  
171 into Public Health England's (PHE) Second Generation Surveillance System (SGSS).  
172 Testing data from sites on SIREN participants is obtained by the PHE SIREN team through  
173 deterministic linkage, based on the NHS number (or equivalent unique identifier for Devolved  
174 Administrations) and additional patient identifiers provided by participants in the enrolment  
175 questionnaire. Linkage to site testing data for participants in Devolved Administrations is  
176 organised with the support of their respective public health agencies. At enrolment,  
177 participants consent for the SIREN team to link all their historic and future SARS -CoV-2  
178 testing data, including tests undertaken prior to enrolment, and tests taken outside SIREN,  
179 such as tests taken due to symptoms or exposures.



## 180 2.5. Testing at Public Health England

### 181 **Serology**

182 For all participants, at enrolment an aliquot of 2ml serum will be shipped to and stored in the  
183 PHE biobank. At follow-up, serum samples for participants who have ever been antibody  
184 positive or antigen positive or have enrolled in a vaccine trial will be sent to and stored at the  
185 PHE biobank.

186 At enrolment, all participants will have their serum re-tested by PHE for antibodies to SARS-  
187 CoV-2, including the Roche Elecsys Anti-SARS-CoV-2 spike (S) and nucleocapsid (N)  
188 protein assays(16) and additional in-house assays to examine for neutralising antibody.  
189 Individuals will be classified as seropositive or seronegative based on PHE antibody testing  
190 for N and S.

191 In addition to the cohort serological characterisation at enrolment described above,  
192 seropositive participants in whom reinfection is identified, plus a cohort of matched non-  
193 infected seropositive controls, will have their sera further characterised using additional  
194 assays and for the presence of neutralising antibody, to provide hypothesis generating data  
195 on mechanisms of protective immunity.

### 196 **Genomic analysis**

197 All positive samples from participants will be sequenced as part of the routine sequencing of  
198 NHS residual samples in COG-UK Consortium laboratories. For participants who have more  
199 than one positive PCR test, genomes will be compared where possible to provide evidence  
200 to support reinfection or persistent infection. Phylogenetic analysis of SARS -CoV-2 from  
201 staff in healthcare organisations, using the study samples and the wider collection of  
202 genomes available through the COG-UK Consortium, will also be undertaken as an  
203 exploratory analysis into the diversity and spread of SARS -CoV-2 in healthcare workers.

204 **Viral Culture**

205 Participants with possible reinfection or persistent infection will be identified and viral culture  
206 requested. This may be on residual sample from the swab already taken, but in certain  
207 circumstances (e.g. viral culture not possible on the residual sample) we may request  
208 another swab is taken and sample sent for culture.

209 **T-cell assays and other studies**

210 Participants who are persistently NAAT positive, have potentially been reinfected, or have  
211 discordant serology may be contacted by the SIREN Study Team to link into optional  
212 regional sub-studies e.g. assessing T cell assays and antibody dynamics.

213

214 **2.6. Sample size and power**

215 A simulation approach using a mixed effects Poisson regression model has been used to  
216 estimate the power to detect relative differences between the study cohorts. Our key  
217 assumptions include that 25% of our cohort will be seropositive at enrolment (based on 20%  
218 of staff who were asymptomatic and tested positive in one London hospital between 23  
219 March and 2 May 2020(14)), and a total attrition of 35%, (unaffected by serostatus and  
220 occurring at a constant rate). The proportion of seropositive recruits at each site has been  
221 obtained from a Gaussian distribution with a mean of 0.25 and standard deviation of 0.05 to  
222 reflect expected inter-site variation.

223 Power was estimated as the proportion of simulations for which the Wald statistic p value for  
224 the estimated incidence rate ratio in the seropositive compared to seronegative cohorts was  
225 less than 0.05. Our simulations found that there is statistical power of 80% or greater to  
226 detect a relative decrease of 30% or greater in cumulative incidence, provided the  
227 cumulative incidence in the seronegative group is in excess of 5%; even taking the  
228 cumulative incidence to as low as 2% in the seronegative group there is still sufficient power  
229 of in excess 80% for relative decrease of 80% or greater.

230 It was assumed that on average 250 participants would be recruited from each selected  
231 healthcare organisation, with a standard deviation of 50. The cumulative incidence in each  
232 site in the seronegative cohort has been simulated using Gaussian distributions with means  
233 of 0.05, 0.1, 0.2 and 0.3 each with a coefficient of variation of 0.2. This range represents that  
234 which is feasible to observe over a 12-month period, given the behavioural and social  
235 interventions still being employed during the study to control transmission.

236 A study duration of 52 weeks has been assumed with the inter-test period of 2 weeks.

237 It was assumed that the cumulative incidence in the seronegative cohort was 30% with a  
238 between trust coefficient of variation of 0.1, reflecting levels of seropositivity in HCWs at the  
239 time. Relative reductions in cumulative incidence in the seropositive cohort was varied  
240 between 1 (no protection from infection) to 0.1 (antibody effectiveness of 90%). Units in the  
241 simulations were allocated to be infected or not, using a draw from a Bernoulli distribution  
242 with  $p$  equal to the site and cohort specific simulated cumulative infection rate. A simplifying  
243 assumption of a constant infection rate over the study period has been used.

244 For each scenario a set of 200 simulations were performed. For each simulation, the total  
245 number of infections and person weeks of follow-up was calculated for each cohort in each  
246 organisation. This data was analysed using a mixed effects Poisson model, using the natural  
247 logarithm of the person weeks as an offset. These are presented in Table 1, indicating that  
248 there is sufficient power for all but the smallest immune efficacy of 0.1 i.e. a 10% reduction in  
249 incidence in the seropositive cohort. Such a small reduction is indicative of a level of  
250 protection unable to provide a means of controlling the pandemic via natural herd immunity.

251

252 **Table 1: Power estimates obtained via simulation for a range of immune**  
253 **effectiveness and cumulative incidence**

Cumulative incidence in the seronegative at baseline cohort (per 100 participants) in 12 months	Immune Effectiveness				
	10%	20%	30%	40%	50%
0.05	0.15	0.44	0.79	0.98	1.00
0.1	0.20	0.77	0.99	1.00	1.00
0.2	0.53	0.99	1.00	1.00	1.00
0.3	0.67	1.00	1.00	1.00	1.00

254

255 **2.7. Statistical Analysis Plan: primary outcome measure**

256 All enrolled participants will be included in analyses, which will account for clustering by  
257 research site. Analyses will be conducted at regular intervals following sufficient events of  
258 interest.

259 Estimates of both cumulative incidence and incidence density in the seropositive and  
260 seronegative cohorts will be obtained using mixed effects models assuming counts of PCR  
261 positive have a negative binomial distribution, a log link function, and the natural logarithm of  
262 the total number of subjects or the total follow-up time use as an offset, respectively.

263 Inclusion of a binary predictor indicating the serostatus of the cohort into this model will  
264 provide estimates of the incidence rate ratio. Sites will be incorporated as a random intercept  
265 to account for unmeasured, shared, site level factors. To account for a non-constant force of  
266 infection, calendar month will be incorporated as an additional random effect. An  
267 assessment of the role of factors such as age, gender and ethnicity in immunity will be  
268 explored by inclusion of interactions within the model between each and serological status.

269 While the above analytical approaches provide a “classical” person-years approach to  
270 prospective cohort analysis and provide familiar measures of association, it may be  
271 inadequate to assessment of immunity provided by seroconversion. As it is expected that  
272 seropositivity is likely to confer a degree of short to median term protection for a SARS-CoV-

273 2 infection, multi-state and parametric cure rate models incorporating frailty will also be  
274 employed. Bayesian approaches to cure rate models with frailty as describe by deSouza(17)  
275 will be employed.

276 It is also possible to introduce “misclassification” of state into the multi state model, providing  
277 an estimate of sensitivity to account for imperfect serological tests. Approaches like those  
278 proposed by Jackson(18) will be employed.

### 279 **Procedure for Accounting for Missing, Unused, and Spurious Data**

280 Analyses will be restricted to cases with antibody and PCR tests. The PCR test for virus is  
281 being used as a diagnostic test and hence has high performance. Sufficient sera will be  
282 obtained to re-run the immunological assays in case of initial assay failure. For similar  
283 reasons we do not anticipate that spurious data will be obtained.

### 284 **Procedures for Reporting any Deviation(s) from the Original Statistical Plan**

285 Deviations from the original statistical plan or the statistical analysis plan will be described  
286 and justified in the analysis reports.

287 Data will be analysed using STATA.v15 and R software.

288

## 289 **3. Study oversight**

290 Oversight is provided by the Study Management Group, chaired by the Chief Investigator,  
291 with representatives from Public Health England, Public Health Scotland, Public Health  
292 Wales, Public Health Agency (Northern Ireland), and the COVID-19 Genomics Consortium  
293 UK (COG-UK).

294 The study follow-up period will end by default 12 months following the enrolment of the last  
295 participant, but by consensus of the Study Management Group and funder may be  
296 terminated sooner if findings are sufficient. There are no formal stopping rules for futility,

297 utility or lack of power. The final decision to terminate the study will be made by Public  
298 Health England and Department for Health and Social Care.

299

## 300 4. Ethics and Consent

301 The study has received approval from Berkshire Research Ethics Committee and has also  
302 received support from NIHR as an urgent public health study, which allows central research  
303 network resources to recruit participants. All participants have provided informed consent  
304 prior to entry to the study and have the option to withdraw at any time. At withdrawal,  
305 participants can choose to have their data or samples retained or destroyed, or partial  
306 variations. Protocol deviations and breaches will be recorded by the site research teams and  
307 the Sponsor will be informed of any serious breaches within one working day.

308

## 309 5. Discussion

### 310 5.1. Strengths

311 This study is the largest national longitudinal study of this scale examining the question of  
312 reinfection with SARS -CoV-2 that the authors are aware of globally. In a system where staff  
313 members may be tested in different settings depending on the timing and reasons for testing  
314 (community testing hubs, other hospitals, primary care), the automated method of data  
315 extraction and access to national testing data means that the study is less likely to miss  
316 potential cases. As far as possible the study is designed to run alongside normal laboratory  
317 processes; laboratories use the same assays and procedures which are in place for all other  
318 testing, reducing additional burden on sites.

319 The study design lends itself to forming sub-cohorts for more detailed investigations. It has  
320 active research collaborations with immunology researchers from the UK Research and

321 Innovation (UKRI) Immunology consortium to investigate T cell responses and with the  
322 Wellcome Trust funded Humoral Immune Correlates of COVID-19 (HICC) consortium to  
323 investigate humoral immune responses.

324

## 325 5.2. Weaknesses

326 Cohort retention will be an important consideration for the study team, to avoid losing power  
327 to detect the primary outcome and potential introduction of bias if there is differential attrition  
328 by cohort. To mitigate this, the study team will actively monitor withdrawals and participant  
329 feedback, to implement improvements and will establish direct participant communications  
330 (e.g. a newsletter) to promote engagement. Over the study period, it is likely that vaccine  
331 trials and usage will increase; adjustments to the study methodology may be required to  
332 permit co-enrolment and retain SIREN participants who subsequently receive vaccines, and  
333 to incorporate vaccine efficacy into the analyses. Differences in demographics, general  
334 health and ongoing risk of exposure between healthcare workers and the general population  
335 mean that the results may not be fully generalisable to the UK population.

336

## 337 6. Declarations

### 338 6.1. Ethics

339 The study has received ethical approval from Berkshire Research Ethics Committee  
340 (20/SC/0230). Study participants will provide informed written consent prior to study entry.

### 341 6.2. Competing Interests

342 The authors have no competing interests to declare

343        6.3.        Funding

344        The study is funded by the Department of Health and Social Care and Public Health  
345        England, with contributions from the Scottish, Welsh and Northern Irish governments.

346        6.4.        Authors' contributions

347        SH is the Chief Investigator and conceived the study. SH, CB, and MAC designed the study  
348        and drafted the first protocol, with substantial design contribution from MR, MZ and TB. AC  
349        wrote the statistics plan and power calculations. VH, SW, MJC, PK, MS, SR, BO and AV  
350        were responsible for designing or updating aspects of the study design. SW and VH re-  
351        drafted the most recent protocol. SH, SW and VH prepared the manuscript for publication,  
352        with the review and approval of the other authors.

353        6.5.        Authors' Acknowledgements

354        The authors would like to thank our partners in the Devolved Administrations, particularly  
355        Lesley Price and Muhammad Sartaj, for their contribution and advice.

356        6.6.        Availability of Data

357        Not applicable

358        6.7.        Consent for Publication

359        Not applicable

360



## 361 7. References

- 362 1. Government of the Hong Kong Special Administrative Region. CHP closely monitors  
363 cluster of pneumonia cases on Mainland 31/12/2019 2019 [updated 31/12/2019].  
364 Available from: <https://www.info.gov.hk/gia/general/201912/31/P2019123100667.htm>.
- 365 2. World Health Organization. COVID-19 Dashboard 2020 [4/12/2020]. Available from:  
366 <https://covid19.who.int/>.
- 367 3. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B,  
368 Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct  
369 strain. *Clin Infect Dis*. 2020.
- 370 4. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a  
371 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome  
372 sequencing. *Clin Infect Dis*. 2020.
- 373 5. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Márquez S, Gutierrez B, Rojas-Silva P,  
374 et al. A case of SARS-CoV-2 reinfection in Ecuador. *Lancet Infect Dis*. 2020.
- 375 6. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A Case of  
376 Early Re-infection with SARS-CoV-2. *Clin Infect Dis*. 2020.
- 377 7. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic  
378 evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis*. 2020.
- 379 8. Gupta V, Bhojar RC, Jain A, Srivastava S, Upadhayay R, Imran M, et al. Asymptomatic  
380 reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2.  
381 *Clin Infect Dis*. 2020.
- 382 9. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining  
383 prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults.  
384 *medRxiv*. 2020:2020.10.26.20219725.
- 385 10. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal  
386 observation and decline of neutralizing antibody responses in the three months following  
387 SARS-CoV-2 infection in humans. *Nat Microbiol*. 2020;5(12):1598-607.

- 388 11. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et  
389 al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*.  
390 2020;383(18):1724-34.
- 391 12. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections.  
392 *Immunity*. 2020;53(2):248-63.
- 393 13. Shields A, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-CoV-2  
394 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional  
395 study. *Thorax*. 2020;75(12):1089-94.
- 396 14. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ, et al.  
397 Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS  
398 Trust. *Infect Control Hosp Epidemiol*. 2020:1-3.
- 399 15. Houlihan CF, Vora N, Byrne T, Lewer D, Kelly G, Heaney J, et al. Pandemic peak SARS-  
400 CoV-2 infection and seroconversion rates in London frontline health-care workers.  
401 *Lancet*. 2020;396(10246):e6-e7.
- 402 16. Public Health England, University of Oxford. Evaluation of sensitivity and specificity of  
403 four commercially available SARS-CoV-2 antibody immunoassays. 2020.
- 404 17. de Souza D, Cancho VG, Rodrigues J, Balakrishnan N. Bayesian cure rate models  
405 induced by frailty in survival analysis. *Stat Methods Med Res*. 2017;26(5):2011-28.
- 406 18. Jackson CH. Multi-State Models for Panel Data: The msm Package for R. *Journal of*  
407 *Statistical Software*. 2011;38(8):1-28.